uPAR / PLAUR (Protein | Antibody | cDNA Clone | ELISA Kit)

All uPAR / PLAUR reagents are produced in house and quality controlled, including 18 uPAR / PLAUR Antibody, 2 uPAR / PLAUR ELISA, 26 uPAR / PLAUR Gene, 1 uPAR / PLAUR IP Kit, 3 uPAR / PLAUR Lysate, 3 uPAR / PLAUR Protein, 2 uPAR / PLAUR qPCR. All uPAR / PLAUR reagents are ready to use.

uPAR / PLAUR Background

Urokinase plasminogen activator (uPA) and/or its receptor (uPAR) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. uPAR and uPA levels in both resected tumor tissue and plasma are of independent prognostic significance for patient survival in several types of human cancer. This system has classically been thought to drive tumor progression by mediating directed extracellular proteolysis on the surface of migrating or invading cells, and intervening with this proteolysis by targeting uPAR has been proposed to represent a novel approach for inhibiting tumor progression. uPAR, also known as PLAUR or CD87, has been implicated in the growth, metastasis, and angiogenesis of several solid and hemotologic malignancies. uPAR is a highly glycosylated, 55-6kDa integral membrane protein linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. It is part of a cell surface system that also consists of the serine protease uPA and several specific inhibitors (plasminogen activator inhibitors 1 and 2). Additionally, the analysis of CD87 (urokinase-type plasminogen activator receptor - uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma.

uPAR / PLAUR References

  • Romer J, et al. (2004) The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des. 10(19): 2359-76.
  • Bn MC, et al. (2004) CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia. 18(3): 394-400.
  • Pillay V, et al. (2007) The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol. 25(1): 33-9.
  • Mazar AP. (2008) Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res. 14(18): 5649-55.
彩票大奖得主捐赠 黑龙江11选5购买 超级大透乐开奖结果 同花顺炒股软件官网 快三预测软件免费 北京快3属于正规彩票吗 002552新浪财经 甘肃快三选号技巧 股票短线的技巧 重庆时时全天计划 宁夏11选5网上购彩